Tandem Meetings 2023 | Impact of belumosudil on tacrolimus & sirolimus pharmacokinetics in patients with chronic GvHD
Rebecca Gonzalez, PharmD, BCOP, Moffitt Cancer Center, Tampa, FL, comments on the results of a study investigating drug interactions between belumosudil and tacrolimus and/or sirolimus in patients with chronic graft-versus-host disease (GvHD). Overall, the study reported that belumosudil impacts these agents’ pharmacokinetics requiring dose adjustments. These findings suggest that empiric dose reductions should be considered for sirolimus and tacrolimus when belumosudil is co-administered. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
